Testosterone Enanthate Re-Titration After Stopping

Why You Cannot Simply Resume Your Old Dose

Returning to a previous maintenance dose without re-titration is the most common mistake men make after a treatment break. The body does not pause in the same state it was in when therapy stopped. Two main changes occur during a gap in testosterone replacement therapy (TRT).

HPG Axis Recovery Is Unpredictable

If the break lasted 8 weeks or longer, the hypothalamic-pituitary-gonadal axis may have partially reactivated. A 2016 analysis within the Testosterone Trials (TTrials) showed that older men with confirmed hypogonadism (total testosterone <275 ng/dL) had variable endogenous recovery after discontinuing exogenous testosterone, with some participants reaching mid-range levels and others falling back below 200 ng/dL within 12 weeks [1]. The degree of recovery depends on age, duration of prior TRT, and whether primary or secondary hypogonadism is the underlying diagnosis.

Androgen Receptor Sensitivity Resets

Androgen receptor density and sensitivity upregulate during periods without exogenous testosterone. Jumping straight to a dose of 100 to 200 mg per week in this context can produce supraphysiologic peaks, erythrocytosis, estradiol spikes, and exaggerated side effects that were absent at the same dose before the break [2]. Starting low allows the receptor environment to readjust gradually.

The Endocrine Society's 2018 clinical practice guideline recommends titrating testosterone therapy to achieve trough levels of 400 to 700 ng/dL, with dose adjustments no more frequently than every 6 to 8 weeks to allow steady-state pharmacokinetics to stabilize [3]. This guidance applies to initial starts and restarts alike.

Pre-Restart Assessment: What Labs to Draw Before the First Injection

Before the first injection after a break, a focused lab panel confirms whether TRT is still indicated and establishes a fresh safety baseline. Do not skip this step. A man whose endogenous production recovered to 450 ng/dL during a 6-month break may not need to restart at all.

Required Baseline Labs

Draw these fasting, between 7:00 and 10:00 a.m.:

• Total testosterone (LC-MS/MS preferred)
• Free testosterone (equilibrium dialysis or calculated from SHBG and albumin)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Complete blood count with hematocrit
• Comprehensive metabolic panel including liver enzymes
• Estradiol (sensitive assay, LC-MS/MS)
• PSA (mandatory if age 40 or older, per AUA/Endocrine Society overlap guidance)
• Lipid panel

When to Add Extra Tests

If the break was longer than 6 months, add a DEXA scan request for men over 50 who had osteopenia documented before therapy. Testosterone withdrawal can accelerate bone mineral density loss in hypogonadal men, as shown in the bone sub-study of the TTrials [4].

If prior TRT was discontinued because of erythrocytosis (hematocrit above 54%), confirm that the hematocrit has normalized before restarting. The FDA-mandated labeling for testosterone enanthate (Delatestryl) lists polycythemia as a known risk requiring periodic monitoring [5].

The Re-Titration Protocol: Week by Week

This protocol applies to testosterone enanthate administered once weekly via intramuscular (IM) or subcutaneous injection. Clinic protocols vary, but the following schedule aligns with the Endocrine Society 2018 guideline and published TRT titration arms [3].

Weeks 1 Through 6: Conservative Restart

Begin at 50 mg per week if the break exceeded 12 weeks, or 75 mg per week if the break was 4 to 12 weeks. The lower starting dose accounts for greater HPG axis and receptor reset in longer breaks.

Administer on the same day each week. Morning injections are not pharmacologically necessary for enanthate (unlike lab draws for endogenous testosterone), but consistency in timing helps maintain stable trough-to-peak ratios.

Week 6: First Trough Lab Draw

Draw labs on the morning of the scheduled injection, before administering the dose. Measure total testosterone, free testosterone, hematocrit, estradiol, and liver enzymes. Compare the trough total testosterone to the 400 to 700 ng/dL target window.

• Trough <400 ng/dL: Increase the dose by 20 to 25 mg per week.
• Trough 400 to 700 ng/dL with symptom improvement: Hold the current dose. This is your maintenance dose.
• Trough >700 ng/dL: Reduce by 10 to 25 mg per week. Supraphysiologic troughs on a low restart dose suggest significant endogenous contribution; reassess whether ongoing TRT is needed.
• Hematocrit >50% but <54%: Continue but recheck in 4 weeks. Consider therapeutic phlebotomy if trending upward.
• Hematocrit ≥54%: Hold therapy. Do not dose-escalate. Refer for hematologic evaluation if the reading does not normalize within 4 to 6 weeks of holding.

Weeks 12 Through 14: Second Trough Lab Draw

Repeat the same panel. If a dose change was made at week 6, this draw assesses the new steady state. Testosterone enanthate reaches pharmacokinetic steady state in approximately 4 to 5 half-lives. With a half-life of roughly 4.5 days, that translates to about 3 weeks. A week-12 draw provides comfortable margin [5].

Most men reach a stable maintenance dose within two to three titration cycles. Only a small fraction (roughly 10 to 15% in clinic cohort data) require more than three adjustments [6].

Ongoing Monitoring After Stabilization

Once stable, the Endocrine Society recommends labs at 3 to 6 months, then annually. Each visit should include total testosterone, hematocrit, PSA (age 40+), and estradiol. Lipid panels should be drawn annually or more often in men with dyslipidemia at baseline [3].

Dose Escalation Specifics: How Quickly Can You Increase Testosterone Enanthate?

The minimum safe interval between dose changes is 6 weeks. Faster escalation risks overshooting the target because the previous dose has not yet reached steady state. A common clinical error is adjusting at 3 or 4 weeks, seeing a trough that reflects a transitional (not steady-state) level, and making a second premature adjustment.

Typical Escalation Increments

| Scenario | Starting Dose | Increment | Max Single Adjustment | |---|---|---|---| | Long break (>12 weeks) | 50 mg/week | 20 to 25 mg | 25 mg | | Short break (4 to 12 weeks) | 75 mg/week | 15 to 25 mg | 25 mg | | Sub-therapeutic at week 12 | Current dose | 10 to 20 mg | 20 mg | | Hematocrit 50 to 53% | Current dose | Hold or reduce | Reduce 25 mg |

The ceiling for standard TRT dosing is generally 200 mg per week, though few men need this much to achieve trough levels in the 400 to 700 ng/dL window. The TTrials used a gel formulation, but pharmacokinetic modeling studies have established equivalent target ranges for enanthate injections [1][7].

Subdividing the Weekly Dose

Some clinicians split the weekly dose into two injections (e.g., 37.5 mg every 3.5 days instead of 75 mg once weekly). Splitting reduces peak-to-trough fluctuation, which may lower estradiol conversion at the peak and reduce hematocrit rise. A 2017 pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that twice-weekly dosing of testosterone cypionate (pharmacokinetically similar to enanthate) reduced peak testosterone by approximately 30% while maintaining equivalent trough levels [8]. This approach can be useful during re-titration if a man previously experienced estradiol-related side effects (nipple sensitivity, water retention, mood instability) on once-weekly dosing.

Managing Estradiol During Re-Titration

Estradiol management is often the most challenging part of re-titration. Aromatase activity in adipose tissue converts testosterone to estradiol, and this process may be amplified during the restart window when receptor sensitivity is heightened.

Target Range and Red Flags

The optimal estradiol range during male TRT is approximately 20 to 35 pg/mL by sensitive assay. Values above 40 to 50 pg/mL with symptoms (gynecomastia tenderness, bloating, emotional lability) may warrant intervention.

First-line management is dose reduction or frequency splitting, not automatic addition of an aromatase inhibitor (AI). The Endocrine Society guideline does not recommend routine AI use during TRT because of concerns about bone mineral density loss with chronic estradiol suppression [3]. A 2020 retrospective cohort study in 400 men on TRT found that those using anastrozole concurrently had a 1.9-fold higher rate of osteopenia progression at 24 months compared to matched controls on TRT alone [9].

When an AI May Be Appropriate

Short-course, low-dose anastrozole (0.25 mg twice weekly for 4 to 6 weeks) may be considered if estradiol exceeds 60 pg/mL with moderate-to-severe symptoms and dose reduction alone is insufficient. Recheck estradiol 4 weeks after initiating the AI. Discontinue as soon as levels fall below 40 pg/mL.

Special Situations That Change the Re-Titration Approach

Not every restart follows the standard protocol. Several clinical scenarios require modifications.

Restart After Fertility-Driven Discontinuation

Men who stopped TRT to restore spermatogenesis (often with the addition of hCG, clomiphene, or enclomiphene during the washout) may have partial HPG axis recovery and residual gonadotropin stimulation. Draw LH, FSH, and a semen analysis before restarting. If the couple has conceived or sperm parameters have met their target, resume TRT at 50 to 75 mg per week per the standard protocol. If LH is elevated (>10 mIU/mL) and total testosterone is still low, primary hypogonadism is confirmed, and the restart dose can begin at 75 mg [3].

Restart After a Cardiovascular Event

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and established or high-risk cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months [10]. This data supports restarting TRT after a cardiovascular event once the patient is medically stabilized, though closer monitoring of hematocrit and blood pressure is warranted. Start at the lower end (50 mg/week) and extend the titration interval to 8 weeks.

Restart After Erythrocytosis-Related Hold

If the prior hold was triggered by hematocrit ≥54%, confirm normalization (<50%) before restarting. Resume at 50 mg/week regardless of prior maintenance dose. Check hematocrit at 4 weeks (not the standard 6) because early erythropoietic response predicts future trajectory [5]. If hematocrit rises above 50% again on the restart dose, consider twice-weekly injection splitting and a hematology referral to rule out concurrent polycythemia vera or chronic hypoxia.

Symptom Timeline: What to Expect After Restarting

Symptom improvement does not track a single timeline. Different androgen-responsive domains recover at different rates. A 2011 systematic review in the European Journal of Endocrinology mapped the expected onset and plateau of testosterone therapy effects [11]:

• Libido improvement: 3 to 6 weeks (plateau at 6 to 12 months)
• Energy and mood: 3 to 6 weeks (plateau at 12 to 18 months for depressive symptoms)
• Erection quality: 6 to 12 weeks (may take up to 6 months)
• Lean body mass gains: 12 to 16 weeks (plateau at 6 to 12 months)
• Bone mineral density: 6 to 12 months (plateau at 24 to 36 months)
• Lipid changes: 4 to 8 weeks for triglycerides; LDL may take 12 to 24 months

Men restarting therapy sometimes report that the initial weeks feel more potent than their original start. This is consistent with the upregulated androgen receptor hypothesis. The sensation typically normalizes within 4 to 8 weeks as receptor density downregulates to a new set point.

When Re-Titration Should Be Supervised by an Endocrinologist

Primary care and telehealth TRT management is appropriate for straightforward re-titrations. Refer to an endocrinologist if any of the following apply:

• Persistent hematocrit >52% on doses ≤75 mg/week
• PSA rise >1.4 ng/mL within 12 months of restart (per AUA guidance) [12]
• Failure to achieve trough testosterone >400 ng/dL on 150 mg/week
• Suspected secondary hypogonadism with pituitary imaging findings
• Concurrent growth hormone deficiency or adrenal insufficiency
• Age <25 (rare indication; requires specialist oversight)

The AUA's 2018 guideline on testosterone deficiency recommends shared decision-making and documented informed consent before initiating or restarting TRT, including discussion of fertility effects, erythrocytosis risk, and the current evidence on cardiovascular safety [12].